40% faster hemostatis7*
Discover the value of laser therapy in BPH
Compared to TURP, laser therapy has shown shorter hospitalisation and catheterisation times. Studies reporting median catheterisation times of 22 hours versus 46,7 hours and 90% success rate in same day catheter removal.1,2
Patient satisfaction
88% (74/84) of patients were at least mostly satisfied 57 months after treatment with GreenLight XPS.1 to 11
92% (35/38) of patients were highly satisfied with the HoLEP procedure with a mean follow up of 6 years.12
Technological advancements
Lumenis PulseTM 120H Holmium Laser System with MOSESTM Technology provides 15% faster enucleation and 40% quicker hemostasis* than a standard holmium laser.4 The improvements in hemostasis can lead to better vision clarity and control, physicians can learn the HoLEP technique and build confidence after 20 procedures supervised by an experienced urologist.4-6
The GreenLight XPS™ Laser Therapy System has advanced technical specifications, with a maximum power of 180W and an improved beam geometry of the MoXyTM fiber.3
Durable efficacy
The Lumenis Pulse™ 120H Holmium Laser System delivers the long-term benefits of HoLEP.10
HoLEP with MOSES laser, in comparison to standard, provides excellent and durable clinical outcomes (PVR, Qmax, IPSS, and QoL).10
Symptom relief and quality of life improvements vs baseline were maintained at 5 years.9,11
40%
p<0.001
15%
p=0.01
15% faster enucleation7*
0.7%
re-operation rate 14**
90+%
same-day discharge7
HoLEP demonstrates better outcomes than TURP with regards to hemoglobin loss, bladder irrigation, catheterization time, hospital stay, and blood transfusion.* MOSES™Technology is suited for a broad range of prostate sizes and patient types, including patients with large prostates and patients treated with anticoagulants, transforming the way BPH is manage 12, 13
*among patients with small to midsized prostates
Long-term improvements in symptoms with GreenLight XPSTM 9,11
Symptom relief and quality of life improvements vs baseline were maintained at 5 years.9,11
75.2%
reduction in mean IPSS9
International Prostate Symptom Score
72.7%
72.7% improvement in mean Qmax9
Peak Urinary flow rate
78.72%
Increase in QOL9
Quality of life score
1-4.8%
re-intervention rate9,11
Surgical interventions following PVP
How can we help you?
References
1. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomized Trial -The GOLIATH Study. Eur Urol. 2014;65(5):931–942.
2. Catheter Removal on the Same Day of Holmium Laser Enucleation of the Prostate: Outcomes of a Pilot Study by Deepak K. Agarwal, Marcelino E. Rivera, Charles U. Nottingham, Tim Large, and AmyE.Krambeck in Urology. 2020 Dec; 146: 225–229) 7. Data on File with Boston Scientific.
3. Data on file with Boston Scientific
4. Large T, Nottingham C, Stoughton C, et al. Comparative study of holmium laser enucleation of the prostate with MOSES enabled pulsed laser modulation. Urology. 2020;136:196–201.
5. Nevo A, Faraj KS, Cheney SM, et al. Holmium laser enucleation of the prostate using MOSES 2.0 vs non‐MOSES: a randomised controlled trial. BJU Int. 2021;127(5):553–559.
6. El‐Hakim A, Elhilali MM. Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int. 2002;90(9):863–869.
7. GreenLight XPS Directions for Use.
8. Lumenis Pulse Directions for Use.
9. Ajib K, Mansour M, Zanaty M, et al. Photoselective vaporization of the prostate with the 180-W XPS Greenlightlaser: Five-year experience of safety, efficiency and functional outcomes. Can Urol Assoc J. 2018;12(7):E318–E324.
10. Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol. 2011;186(5):1972–1976.
11. Calves J, Thoulouzan M, Perrouin-Verbe MA, et al. Long-Term Patient-Reported Clinical Outcomes and Reoperation Rate After Photovaporization with the XPS-180W GreenLight Laser. Eur Urol Focus. 2019;5(4):676–680.
12. Gilling PJ, Aho TF, Frampton CM, et al. Holmium Laser Enucleation of the Prostate: Results at 6 Years. Eur Urol. 2008;53(4):744–749
13. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline 2021. J Urol. 2021;206:806
The MOSES™ 2.0 Technology is inclusive of all MOSES™ 1.0 settings and features. Boston Scientific acquired the global surgical business of Lumenis Ltd. Lumenis Pulse™ 120H is the registered product name. Lumenis Pulse™ 120H is manufactured and sold by Boston Scientific. Lumenis is a registered trademark of Lumenis Be.
Rx only.
CE 0344
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners